[3] Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study. Retrieved December 8, 2019, form https://www.businesswire.com/news/home/20191207005032/en.

[4] Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma. Retrieved December 8, 2019, from https://www.businesswire.com/news/home/20191206005463/en/Bristol-Myers-Squibb-bluebird-bio-Announce-Positive-Top-line

[5] New Approaches Aim to Enhance CAR T-Cell Therapy. Retrieved December 8, 2019, from https://www.hematology.org/Newsroom/Press-Releases/2019/10096.aspx

原标题：ASH | 缓解率100%！杨森/南京传奇CAR-T疗法结果惊艳，BMS两款CAR-T疗法将递交监管申请

▽关注【药明康德】微信公众号